Kuros Biosciences is a Swiss-headquartered biotech/medtech company focused on biologic bone graft technologies, in particular its MagnetOs product line, which uses an osteoimmunology-based surface technology (“NeedleGrip”) to harness the immune system (e.g., M2 macrophage response) and stimulate reliable bone regeneration for spine, extremities, trauma and oncology indications; the company develops and commercializes these grafts in multiple formats (granules, putty, Easypack, Flex Matrix) across 20+ markets and is listed on the SIX Swiss Exchange under the ticker KURN.

Kuros Biosciences was founded in March 2000 as a spin‑off from the Swiss Federal Institute of Technology in Zurich (ETH Zurich); publicly available materials describe the company’s origin as that institutional spin‑off but do not clearly list named individual founders, so specific founder names are not definitively disclosed in current official or major secondary sources.